Earnings Releases·Oct 28, 2026, 4:07 PM ET

Bausch Health — Third Quarter 2026 Earnings Summary

Consolidated revenues rose 10% YoY to $2.94 billion, while GAAP net income surged to $436 million ($1.15 EPS) and adjusted EBITDA increased 32% YoY to $1.305 billion.
The Company raised full-year 2026 guidance for Revenue ($10.975B–$11.175B), Adjusted EBITDA ($4.315B–$4.415B), and Adjusted Cash Flows from Operations ($1.600B–$1.675B).
Bausch Health (excluding Bausch + Lomb) delivered its 14th consecutive quarter of YoY growth, with Adjusted EBITDA exceeding $1 billion for the first time.
Cash and cash equivalents increased to $2.485 billion, and the Board authorized a $50 million share repurchase program to offset anticipated equity dilution.
Management highlighted strong momentum despite risks from potential tariffs, Inflation Reduction Act impacts on Xifaxan pricing in 2027, and ongoing legacy litigation.